Gut commensal microbiota

The *gut commensal microbiota* refers collectively to the diverse and complex community of microorganisms, including bacteria, archaea, viruses, and fungi, that inhabit the gastrointestinal tract and are not typically pathogenic[1][5][3]. These commensal organisms exist in a mutually beneficial relationship with the host, playing critical roles in digestive function, the synthesis of essential vitamins, maintenance of gut barrier integrity, modulation of the immune system, and protection against pathogen colonization[1][3][5]. Gut commensal microbiota also influence host metabolism, xenobiotic and drug transformation, and systemic immune and neuroimmune functions such as the gut–brain axis[1][6][8]. Disruption of this community (dysbiosis) is associated with a range of disorders including inflammatory, metabolic, neurological, and infectious diseases[1][2][4][8]. However, the gut commensal microbiota, as a collective entity rather than an individual molecule or receptor, is not considered a precise “therapeutic target” in the classic sense (e.g., receptor, enzyme), but rather a complex system whose modulation may be therapeutically beneficial[2][4][6][8]. **Note:** - This entry is "incorrect" as a molecular target because *gut commensal microbiota* refers to a broad, heterogeneous community rather than a specific molecule, protein, receptor, or gene. It does not fit the conventionally structured definition of a drug target and instead represents a system or community-level therapeutic concept[6][4]. - Direct molecular targeting typically occurs at the level of a well-defined protein, enzyme, or nucleic acid, while microbiota modulation is a systems-based intervention (e.g., probiotics, antibiotics, FMT)[2][4][6].

Other names

Gut commensal bacteriacommensal microbiotanormal gut floracommensals of the gutintestinal commensal microbiotagut flora

Modulation of community structure to shift function (e.g., probiotics, antibiotics) Inhibition of bacterial enzymes responsible for undesirable drug metabolism (e.g., β-glucuronidase inhibition to prevent CPT-11 toxicity) Restoration of healthy microbiota (e.g., fecal microbiota transplantation)